Genetically Modified Immune Effector Cells Show Long-Term Safety in Study
Thirteen patients in a cohort of 340 cancer patients who received genetically modified immune cells developed 16 secondary cancers in the months or years following treatment, a rate comparable to patients who receive standard-of-care therapies, including chemotherapy and hematopoietic stem cell transplant. Researchers reviewed biopsy results for 11 of the secondary tumors and found no transferred genetic material from the therapy.
Source: genengnews.com